The Montreal-headquartered hormone monitoring technology firm said in a blog post Tuesday it had secured the new funding led by BDC’s Thrive Venture Fund, with Muse Capital, Telus Global Ventures and others as additional investors. The new round, first reported by Axios, brings Eli’s total amount raised to US$20 million. (The Logic)

Talking point: The funding will go toward continuing to grow Eli’s main product—the Hormometer—an instant saliva-based hormone monitor which shares a “live feed” to users through a phone app. It primarily tests cortisol, the stress hormone, and progesterone, which influences the menstrual cycle and overall female health. The Eli app also syncs with various wearable devices and fitness trackers. Eli Health currently has around 20 employees.